KEYNOTE-407 — Pembrolizumab Plus Chemotherapy in Metastatic Squamous NSCLC

Phase 3 · 2018 · Non-Small Cell Lung Cancer

Design

Randomized carboplatin plus paclitaxel/nab-paclitaxel with pembrolizumab or placebo.

Population

Untreated metastatic squamous NSCLC, any PD-L1.

Primary Endpoint

overall survival (OS) and progression-free survival (PFS)

Key Result

OS HR 0.64 (median 15.9 vs 11.3 mo); PFS HR 0.56 (6.4 vs 4.8 mo); benefit across all PD-L1 strata.

Guideline Impact

NCCN category 1 first-line for metastatic squamous NSCLC